This site is intended for health professionals only

Published on 20 November 2015

Share this story:
Twitter
LinkedIn

NOTIFICATION OF PRODUCT DISCONTINUATION

Actavis announce the immediate discontinuation of Rapilysin 10 U powder and solvent for solution for injection.

 

There has been a movement therapeutically in the UK to either ambulatory or hospital determined PCI post suspected MI, and a subsequent reduction in the use of thrombolytic agents of this specific type.

 

Actavis announce the immediate discontinuation of Rapilysin 10 U powder and solvent for solution for injection.

 

There has been a movement therapeutically in the UK to either ambulatory or hospital determined PCI post suspected MI, and a subsequent reduction in the use of thrombolytic agents of this specific type.

 

This has resulted in a production batch size, which far exceeds the total UK annual demand and the drug is no longer commercially sustainable.  No further stock remains in the Actavis UK warehouse.

 

Please note other thrombolytic agents are available within the market and can be ordered through your normal route.

 

If you do have any questions on this announcement, please direct them to:

 

Derek Brown
Director, Hospital Business
Email: derek.brown@actavis.com or telephone on 01628 478321

Yours faithfully

Lisa Harman
Director, Portfolio, Marketing & Business Information



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn